submit news    HOME | FEEDBACK  


« NAVIGATION »
NEWS

- Bio/Medicine

- Chemicals

- Defense

- Drug Delivery

- Education

- Electronics

- Energy

- Events

- Grants

- Industry

- Investment

- Litigation

- Materials

- MEMS

- Nanofabrication

- Nanoparticles

- Nanotubes

- Optics

- Partnership

- Patent

- Products

- Quantum dots

- Research

- Smart Dust

- Software
COMPANIES
EVENTS

- Browse by Month

- Current Shows

- Previous Shows

- Submit Events
FEEDBACK
ADVERTISE
LINK TO US

« PARTNERS »
Become A Nanotechwire Partner

FEI Company

Veeco Instruments

Nano Science and Technology Institute

National Nanotechnology Initiative

Nanotechnology at Zyvex

Want to see your Company or Organization listed above? Become A Nanotechwire Partner Today - click here
« NEWSLETTER »



« SEARCH »







1/15/2007 9:26:16 AM
Dendrimers Improve Cancer Drug Uptake and Antitumor Activity

With an eye toward developing a delivery vehicle for anticancer agents that are poorly soluble in water, a research team at Boston University and the Research Triangle Institute (RTI) has developed a biocompatible dendrimer that wraps itself around water-insoluble drugs. The investigators have used this dendrimer to create water-soluble formulations of three promising anticancer agents belonging to the camptothecin family, which also includes the widely used drugs topotecan and irinotecan. This research is reported in the journal Cancer Research.

David Kroll, Ph.D., of RTI, and Mark Grinstaff, Ph.D., at Boston University, led the team of investigators developing water-soluble dendrimers as drug delivery vehicles. In this instance, the researchers created a dendrimer by polymerizing the natural products succinic acid and glycerol. This dendrimer readily formed stable complexes with three different water-insoluble camptothecins. The encapsulation process increased the water solubility of the drugs by approximately 10-fold.

Tests with four types of cultured cancer cells showed that the dendrimer-drug complexes were readily taken in by the cells. When compared to free drug, up to 16 times more of the encapsulated drug accumulated inside cells within two hours.

More importantly, cultured tumor cells retained a greater percentage of the drug when it was delivered using the dendrimer, a finding that the investigators noted came as a surprise. In one experiment, for example, about 50 percent of the dendrimer-complexed drug that had accumulated within 30 minutes remained in the cell some 32 hours later. In contrast, only 35 percent of the free drug that had accumulated within the first 30 minutes remains inside the cells after 32 hours. Cytotoxicity assays showed that increase in drug accumulation translated into improved potency at killing cancer cells.

This work, which was supported in part by the National Cancer Institute, is detailed in a paper titled, “Dendrimer-encapsulated camptothecins: increased solubility, cellular uptake, and cellular retention affords enhanced anticancer activity in vitro.” Investigators from Duke University and Duke University Medical Center also participated in this study. An abstract of this paper is available through PubMed.

View abstract.

Other Headlines from Boston University ...
 - Expandable Nanoparticles Show Promise in Treating Lethal Abdominal Cavity Tumors
 - New tool detects Ebola, Marburg quickly, easily
 - Leading Edge DNA Sequencing Method Nets Major NIH Grant
 - Boston University biomedical engineers develop new nanopore method for DNA sequencing
 - Professor Studies Proteins Using Nanotechnology

Other Headlines from NCI Alliance for Nanotechnology in Cancer ...
 - Tekmira and the National Cancer Institute Publish Promising Data Demonstrating the Anti-Tumor Activity of a Novel Cancer Target
 - NCI Awards $1.7 Million to Cancer Specialist at Children’s Hospital Los Angeles
 - Nanoparticles Enhance Detection of Circulating Tumor Cells
 - Hand-held NMR Instrument Yields Rapid Analysis of Human Tumors
 - Biodegradable Biopolymer Nanoparticles Hold Promise for Twin Attack on Breast Cancer

More Drug Delivery Headlines ...
 - Independent clinical study validates Nanologica’s new drug carrier material for oral usage
 - Scientists engineer nanoscale vaults to encapsulate 'nanodisks' for drug delivery
 - Yissum Presents Promising Pre-Clinical Results for Oral Delivery of the Anti-Cancer Drug Docetaxel Using a Novel Nanotechnology Approach
 - CEA-Leti and 7 Partners to Study Ways to Improve Treatment of Inflammatory Bowel Disease
 - World first: localized delivery of an anti-cancer drug by remote-controlled microcarriers


« Back To List »

« GET LISTED »
- submit company
- submit news
- submit events
- advertise here

« EVENTS »
- More Events


Copyright © 2014 Nanotechwire.com | Privacy Policy |